Security key
037326105
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 21,894,480
- Total 13F value
- $74,776,572
- Share change
- +13,122,910
- SEC-reported price per share
- $3.42
- Number of holders
- 52
- Value change
- +$47,798,252
- Number of buys
- 34
- Number of sells
- 18
- Shares outstanding
- 36,076,317
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
52
Top holders
10
ANTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
AN2 Therapeutics, Inc. SEC filings
AN2 Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 037326105
Recent filing periods:
Ownership snapshot
Top reported holders of ANTX - AN2 Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Commodore Capital LP
Disclosed value leader
Adjuvant Global Health Te...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.9%
13D/G row: Commodore Capital LP
Showing 1-6 of 15 holder rows.
Quick read
Commodore Capital LP leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Commodore Capital LP's linked filing trail.
Comparable ownership
Top 5
Commodore Capital LP
9.9%
Coastlands Capital Partners LP
9.3%
Vivo Opportunity Fund Holdings, L.P.
8%
Adjuvant Global Health Technology...
7.9%
Eric Easom
7.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Commodore Capital LP |
13D/G
|
9.9%
|
$4,880,614
3,697,435 shares
|
$0 | 09 Mar 2026 |
| Coastlands Capital Partners LP |
13D/G
Coastlands Capital LP
|
9.3%
|
$3,632,511
2,815,900 shares
|
$0 | 28 May 2025 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
8%
|
$3,780,937
2,864,346 shares
|
$0 | 10 Mar 2026 |
| Adjuvant Global Health Technology Fund, L.P. |
3/4/5
13D/G
10%+ Owner · Adjuvant Capital GP, L.P.
|
7.9%
from 13D/G
|
$45,367,317
2,373,500 shares
|
— | 16 Jan 2024 |
| Eric Easom |
13D/G
3/4/5
Chief Executive Officer, Director
|
7.9%
|
$2,946,245
2,232,004 shares
|
+$447,311 | 31 Dec 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
6.3%
|
$2,952,975
2,237,102 shares
|
$0 | 06 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
52
Shares
21,894,480
Rows available
52
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
37
Q1 2026 holders
52
Holder diff
15
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend